Tuesday, September 14, 2010

By Michelle Lang


Advanced Cell Technology Inc. has won two patents related to its stem cell-derived regenerative technology used to treat eye disorders.

The Marlborough company was granted one patent to use human retinal pigment epithelial (RPE) cells differentiated from human embryonic stem cells to treat retinal degeneration, including Stargardt?s disease, retinitis pigmentosa and macular degeneration. The second patent covers ACT?s method of manufacturing RPE cells from human embryonic stem cells for the purpose of transplanting the cells as treatment.

?Our RPE technology is safe and scalable, and has tremendous potential for treating some 200 or more diseases of the retina,? ACT chairman and CEO William Caldwell IV noted in a press release today.

Caldwell said the patents will help ACT in preparing its human clinical trials of RPE cells initially to treat Stargardt?s disease, with plans for a second trial to treat dry Age-Related Macular Degeneration.

ACT (OTC: ACTC) has indicated that the company is not affected by the recent court injunction against federal funding of human embryonic stem cell research.